Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 8
2020 16
2021 6
2022 8
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean pierangelo sepe (1 results)?
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study).
Sepe P, Procopio G, Pircher CC, Basso U, Caffo O, Cappelletti V, Claps M, De Giorgi U, Fratino L, Guadalupi V, Miodini P, De Marco C, Perrucci B, Mennitto A, Santini D, Spina F, Stellato M, de Braud F, Verzoni E. Sepe P, et al. Ther Adv Med Oncol. 2024 Jan 22;16:17588359231217958. doi: 10.1177/17588359231217958. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38264520 Free PMC article.
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.
Fotia G, Stellato M, Guadalupi V, Sepe P, Claps M, Giannatempo P, Bottiglieri A, Rametta A, Taglialatela I, Vela C, Procopio G, Verzoni E. Fotia G, et al. Among authors: sepe p. Curr Oncol Rep. 2023 Jun;25(6):671-677. doi: 10.1007/s11912-023-01395-4. Epub 2023 Mar 31. Curr Oncol Rep. 2023. PMID: 37000341 Review.
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V, De Giorgi U, Bimbatti D, Nolè F, Carrozza F, Buti S, Iacovelli R, Ciccarese C, Masini C, Baldessari C, Doni L, Cusmai A, Gernone A, Scagliarini S, Pignata S, de Braud F, Verzoni E. Procopio G, et al. Among authors: sepe p. Tumori. 2023 Feb;109(1):129-137. doi: 10.1177/03008916221138881. Epub 2022 Nov 29. Tumori. 2023. PMID: 36447337 Free PMC article. Clinical Trial.
Outpatient palliative care referral system (PCRS) for patients with advanced cancer: an impact evaluation protocol.
Brunelli C, Zecca E, Pigni A, Bracchi P, Caputo M, Lo Dico S, Fusetti V, Tallarita A, Bergamini C, Brambilla M, Raimondi A, Niger M, Provenzano S, Sepe P, Alfieri S, Tinè G, De Braud F, Caraceni AT. Brunelli C, et al. Among authors: sepe p. BMJ Open. 2022 Oct 28;12(10):e059410. doi: 10.1136/bmjopen-2021-059410. BMJ Open. 2022. PMID: 36307164 Free PMC article.
Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy.
Bottiglieri A, Sepe P, Stellato M, Pircher C, Fotia G, Leone AG, Guadalupi V, Claps M, Giannatempo P, Verzoni E, Procopio G. Bottiglieri A, et al. Among authors: sepe p. Cancer Manag Res. 2022 Oct 21;14:3071-3081. doi: 10.2147/CMAR.S360441. eCollection 2022. Cancer Manag Res. 2022. PMID: 36275783 Free PMC article. Review.
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors.
Roviello G, Catalano M, De Giorgi U, Maruzzo M, Buti S, Gambale E, Procopio G, Ottanelli C, Caliman E, Isella L, Sepe P, Brighi N, Santoni M, Galli L, Conca R, Doni L, Antonuzzo L. Roviello G, et al. Among authors: sepe p. Front Oncol. 2022 Aug 16;12:918413. doi: 10.3389/fonc.2022.918413. eCollection 2022. Front Oncol. 2022. PMID: 36052244 Free PMC article.
41 results